BREAKING NEWS

BREAKING NEWS

U.S. FDA approves GSK's three-in-one drug inhaler for COPD

Now Reading:

U.S. FDA approves GSK's three-in-one drug inhaler for COPD

Text size Aa Aa

(Reuters) – GlaxoSmithKline Plc <GSK.L> and Innoviva Inc <INVA.O> said on Monday the U.S. Food and Drug Administration has approved their triple drug inhaler for treatment of chronic obstructive pulmonary disease (COPD). GSK’s once-daily triple inhaler, the first to get U.S approval, combines the drugs fluticasone furoate, umeclidinium and vilanterol. It is designed to use three different mechanisms to help open airways of patients with severe COPD. The inhaler, to be sold under the brand name Trelegy Ellipta, was not indicated for relief of acute bronchospasm or treatment of asthma, the companies said in statement. (http://bit.ly/2×9JK84) Last week, the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending the three-in-one inhaled lung drug.

(Reporting by Rama Venkat Raman in Bengaluru; Editing by Leslie Adler)
euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on euronews.com for a limited time.